The Institute for Advanced Clinical Trials for Children Announces the Appointment of Alexandre LeBeaut, MD as
Chief Executive Officer

Rockville, Maryland, May 4, 2021 – The Institute for Advanced Clinical Trials for Children (I-ACT for Children) is pleased to announce the appointment of Alexandre LeBeaut, MD as its new Chief Executive Officer, reporting to the Institute’s Board of Directors. Aligned with I-ACT for Children’s mission, Dr. LeBeaut (“Alex”) will have responsibility for both the strategic direction and execution of the organization’s operations, programs and fundraising while ensuring the organization’s growth, performance and financial sustainability. Dr. LeBeaut is a pediatrician with extensive global research and development expertise, including more than 25 years in the biopharmaceutical industry. He most recently served as Executive Vice President of Research and Development and Chief Scientific Officer at IPSEN BioScience in Cambridge, MA.

“Alex brings a pediatric background, strong scientific knowledge, deep expertise in global product development and many years of successful executive leadership experience to our organization,” said Edward Connor, MD, MBE, I-ACT for Children’s Board Chairman. “He will be at the helm along with Drs. Gary Noel, Chief Medical Officer and Cindy Jackson, Chief Operating Officer, guiding the Institute in achieving our collective mission and vision. We are thrilled to have such a powerhouse executive team working on behalf of the children and families we serve.”

“I could not be more grateful to accept the position as CEO to this well-established organization that consists of a very talented team and history of attracting fully-engaged partners,” said Dr. LeBeaut. “My goal is to build on the achievements of the past three years and to grow the Institute into an even greater, more successful organization, creating lasting impact in pediatrics.”

Alex has a distinguished career in global drug development, having previously held senior leadership positions at Bluebird Bio, Axcan Pharmaceuticals, Sanofi, Novartis, and Schering-Plough Research Institute. Throughout his career, he contributed to develop and successfully bring to patients therapeutic solutions in medical areas including oncology, infectious diseases, pediatrics, genetic diseases, gastroenterology, cardio-metabolic, and neurological disorders.

Dr. LeBeaut received his MD from Paris Diderot University in France and trained in Pediatrics at Paris Descartes University and began his career as a resident fellow in general pediatric and intensive care units in Paris.

About I-ACT for Children

I-ACT for Children is a 501(c)3 that serves as a neutral and independent voice on behalf of children everywhere and is dedicated to advancing new pediatric medicines and devices needed now and in the future. It has built a network of pediatric trial sites designed to accelerate and enhance the quality of pediatric clinical trials. The organization also engages stakeholders from all pediatric research sectors – from regulators, to academia, to industry, to patients – to advance innovative strategies that benefit the pediatric research environment at large.

To learn more about I-ACT for Children, visit http://www.iactc.org.